Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of leadership was required amid fierce glucagon-like peptide 1 receptor ...

LONDON, May 16 (Reuters) - Wegovy-maker Novo Nordisk (NOVOb.CO), opens new tab said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover ...

Novo Nordisk A/S Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board ...

Wegovy-maker Novo Nordisk has pushed out CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. Novo Nordisk ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

May 16 (UPI) --Novo Nordisk announced Friday that CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday that Jorgensen will continue as CEO ...

Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs. The Ozempic maker’s chief executive ...

Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen is stepping down after eight years in the role, during which he led the company to an all-time high in the markets. Despite being the first to ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will resign from the company after a short transition period. His replacement has not yet been found. Novo Nordisk stock is down 50% in 12 months ...

Novo Nordisk and Septerna plan to create new obesity pills that target G protein-coupled receptors (GPCRs), including GLP-1, GIP, and glucagon. HealthDay News — Danish drugmaker Novo Nordisk is ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down as competition in the weight-loss drug space pressured the company's stock. "Considering the recent market challenges, the share price ...